Molecular Partners Past Earnings Performance
Past criteria checks 0/6
Molecular Partners has been growing earnings at an average annual rate of 17.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 34.2% per year.
Key information
17.2%
Earnings growth rate
22.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 34.2% |
Return on equity | -35.1% |
Net Margin | -880.7% |
Next Earnings Update | 26 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Molecular Partners makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7 | -62 | 20 | 0 |
30 Sep 23 | 9 | -60 | 20 | 0 |
30 Jun 23 | 9 | -62 | 21 | 0 |
31 Mar 23 | 20 | -50 | 22 | 0 |
31 Dec 22 | 190 | 118 | 23 | 0 |
30 Sep 22 | 189 | 117 | 22 | 0 |
30 Jun 22 | 190 | 118 | 21 | 0 |
31 Mar 22 | 182 | 106 | 20 | 0 |
31 Dec 21 | 10 | -64 | 18 | 0 |
30 Sep 21 | 9 | -67 | 16 | 0 |
30 Jun 21 | 6 | -72 | 14 | 0 |
31 Mar 21 | 7 | -66 | 12 | 0 |
31 Dec 20 | 9 | -63 | 12 | 0 |
30 Sep 20 | 11 | -53 | 11 | 0 |
30 Jun 20 | 14 | -48 | 12 | 0 |
31 Mar 20 | 17 | -43 | 13 | 0 |
31 Dec 19 | 20 | -36 | 14 | 0 |
30 Sep 19 | 17 | -37 | 13 | 0 |
30 Jun 19 | 14 | -38 | 12 | 0 |
31 Mar 19 | 12 | -38 | 11 | 0 |
31 Dec 18 | 10 | -37 | 10 | 0 |
30 Sep 18 | 17 | -27 | 9 | 0 |
30 Jun 18 | 23 | -18 | 9 | 0 |
31 Mar 18 | 22 | -24 | 9 | 0 |
31 Dec 17 | 20 | -25 | 8 | 0 |
30 Sep 17 | 17 | -26 | 8 | 0 |
30 Jun 17 | 16 | -28 | 7 | 0 |
31 Mar 17 | 19 | -22 | 8 | 0 |
31 Dec 16 | 23 | -19 | 7 | 0 |
30 Sep 16 | 27 | -13 | 22 | 0 |
30 Jun 16 | 31 | -3 | -1 | 0 |
31 Mar 16 | 30 | -2 | 21 | 0 |
31 Dec 15 | 29 | 0 | 6 | 0 |
30 Sep 15 | 28 | -6 | 20 | 0 |
30 Jun 15 | 25 | -11 | 21 | 0 |
31 Mar 15 | 26 | -5 | 15 | 0 |
31 Dec 14 | 27 | -2 | 18 | 0 |
31 Dec 13 | 32 | 7 | 15 | 0 |
Quality Earnings: MLLC.F is currently unprofitable.
Growing Profit Margin: MLLC.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLLC.F is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare MLLC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLLC.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MLLC.F has a negative Return on Equity (-35.13%), as it is currently unprofitable.